Last reviewed · How we verify
NCT05276388
Establishment of a Biological Biobank of Subjects Vaccinated Against SARS-CoV-2 Infection (COVID-19)
trial testing biological bank in Coronavirus Infections in 1,100 participants. Participants enrolled and being followed up; not accepting new ones.
31 December 2022
Quick facts
| Lead sponsor | IRCCS San Raffaele |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 1,100 |
| Start date | 1 January 2021 |
| Primary completion | 31 December 2022 |
| Estimated completion | 31 March 2026 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- biological bank
Conditions studied
- Coronavirus Infections — all drugs for Coronavirus Infections →
Sponsor
IRCCS San Raffaele — full company profile →
Who can join
18 and older, any sex, with Coronavirus Infections. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Establishment of a biological bank of subjects vaccinated against SARS-Cov-2 infection (COVID-BioVac)
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05276388
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coronavirus Infections
Currently open trials in the same condition.
- NCT06631287 — Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Sym · Phase 3 · recruiting
- NCT04429594 — Study of the Incidence of SARS-CoV-2 Infection (COVID-19) · NA · recruiting
- NCT04327570 — In-depth Immunological Investigation of COVID-19. · recruiting
- NCT04318366 — COVID-19 Patients Characterization, Biobank, Treatment Response and Outcome Predictor · recruiting
- NCT04262921 — French COVID Cohort · active not recruiting
Other IRCCS San Raffaele trials
Trials by the same sponsor.
- NCT07454759 — Acute Sarcopenia in Hospitalized Older Adults · not yet recruiting
- NCT07456462 — Making Antibody Treatments More Effective in Early Alzheimer's Disease Using 3Tesla Magnetica Resonance · NA · not yet recruiting
- NCT07066878 — This Protocol Focuses on the Factors That Influence Survival, the Development of Complications and the Quality of Life B · not yet recruiting
- NCT07526298 — Anticipating Irreversible Disability in Neuromyelitis Optica Spectrum Disorder: a Study to Assess Disease Activity in Ap · not yet recruiting
- NCT07426471 — Delafloxacin Plasma and Tissue Concentration in Patients With Skin, Soft Tissue, and Bone and Joint Infections. · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05276388 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by IRCCS San Raffaele
- Last refreshed: 30 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05276388.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing